Pregled bibliografske jedinice broj: 1194931
Clinical characteristics and treatment of lupus nephritis – preliminary analysis of observational data from a National Referral Centre
Clinical characteristics and treatment of lupus nephritis – preliminary analysis of observational data from a National Referral Centre // Acta clinica Croatica. Supplement, 60 (2021), 1; 155-163 doi:10.20471/acc.2021.60.s1.23 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1194931 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Clinical characteristics and treatment of lupus nephritis –
preliminary analysis of observational data from a National
Referral Centre
Autori
Knežević, Tamara ; Padjen, Ivan ; Bulimbašić, Stela ; Ćorić, Marijana ; Ivković, Vanja ; Laganović, Mario ; Anić, Branimir
Izvornik
Acta clinica Croatica. Supplement (0353-9474) 60
(2021), 1;
155-163
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
systemic lupus erythematosus ; lupus nephritis ; treatment ; population characteristics
Sažetak
Lupus nephritis (LN) is one of the most severe features of systemic lupus erythe- matosus (SLE). Data on LN is scarce in the Croatian population. We analysed the characteristics of LN patients diagnosed at our tertiary referral centre. In this retrospective study, we analysed the fol- lowing features of patients with biopsy-proven LN diagnosed between 2011 and 2020: demographics, renal laboratory parameters, renal histopathology, and treatment. A total of 38 patients were included (30 females ; mean age 39±15 years). The most common indi- cation for kidney biopsy was proteinuria (89%). The proportion of LN classes was: class I (2.6%), II (5.3%), III (18.4%), IV (42.1%), V (13.2%), III+V (10.5%), IV+V (5.3%). The median time from SLE diagnosis to histologic confirmation of LN was 1.0 year. All patients were treated with methylpred- nisolone (MP), 68% received MP pulses. Induction treatment included intravenous (IV) cyclophos- phamide (CYC) (71%) (15 patients treated per Euro-Lupus and 9 per the National Institutes of Health regimen), oral CYC (3%), or mycophenolate mofetil (11%). 79% of patients received antima- larials. While there is heterogeneity between different populations, our patient profile was similar to that from other European studies. Further follow-up of this group is necessary to assess outcomes in our population.
Izvorni jezik
Hrvatski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Tamara Knežević
(autor)
Branimir Anić
(autor)
Marijana Ćorić
(autor)
STELA BULIMBAŠIĆ
(autor)
Mario Laganović
(autor)
Vanja Ivković
(autor)
Ivan Padjen
(autor)